Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: Glutathione reduction and MRP1 downregulation

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 676-684

  Wang, Haolu ^a   Li, Xinxing ^a   Chen, Tao ^a   Wang, Wei ^a   Liu, Qiang ^a   Li, Hui ^b   Yi, Jing ^b   Wang, Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Gallbladder cancer; Glutathione; Multidrug resistance related protein 1; Platinum; Verapamil

Indexed keywords

CARBOPLATIN; CISPLATIN; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; GALLBLADDER CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CALCIUM CHANNEL BLOCKERS; CARBOPLATIN; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEIN; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TRANSFECTION; VERAPAMIL;

EID: 84872818677     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2156     Document Type: Article

References (38)

1. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J Surg 196: 252-264, 2008. (Pubitemid 351970506)
2. Zhu AX, Hong TS, Hezel AF and Kooby DA: Current management of gallbladder carcinoma. Oncologist 15: 168-181, 2010.
3. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281, 2010.
4. Hollebecque A, Bouche O, Romano O, et al: Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma. Chemotherapy 56: 234-238, 2010.
5. Andre T, Reyes-Vidal JM, Fartoux L, et al: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 99: 862-867, 2008.
6. Wu CP, Calcagno AM and Ambudkar SV: Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1: 93-105, 2008.
7. Cao L, Duchrow M, Windhovel U, Kujath P, Bruch HP and Broll R: Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur J Cancer 34: 1612-1617, 1998. (Pubitemid 28446347)
8. Wang W, Sun Y P, Huang XZ, et al: Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol 79: 1134-1140, 2010.
9. Aust S, Obrist P, Jaeger W, et al: Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab Invest 84: 1024-1036, 2004. (Pubitemid 39025037)
10. Suzuki T, Nishio K and Tanabe S: The MRP family and anticancer drug metabolism. Curr Drug Metab 2: 367-377, 2001. (Pubitemid 33133981)
11. Zhang K, Mack P and Wong KP: Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 12: 871-882, 1998. (Pubitemid 28133581)
12. Huang XZ, Wang J, Huang C, et al: Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 7: 468-475, 2008. (Pubitemid 351847069)
13. Wang W, Sun Y, Li X, et al: Emodin potentiates the anticancer effect of cisplatin on gallbladder cancer cells through the generation of reactive oxygen species and the inhibition of survivin expression. Oncol Rep 26: 1143-1148, 2011.
14. Quan ZW, Yang Y, Li JY, Gong W, Qin YY and Li SG: The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation. Biomed Pharmacother 64: 451-457, 2010.
15. Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun W: Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol 40: 1501-1514, 2012.
16. Ikeda H, Nakano G, Nagashima K, et al: Verapamil enhancement of antitumor effect of cis-diamminedichloroplatinum(II) in nude mouse-grown human neuroblastoma. Cancer Res 47: 231-234, 1987. (Pubitemid 17002128)
17. Wang J, Wang H, Zhao L, et al: Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res 30: 3593-3598, 2010.
18. Perrotton T, Trompier D, Chang XB, Di Pietro A and Baubichon-Cortay H: (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem 282: 31542-31548, 2007. (Pubitemid 350044880)
19. Chang XB, Hou YX and Riordan JR: ATPase activity of purified multidrug resistance-associated protein. J Biol Chem 272: 30962-30968, 1997. (Pubitemid 27527540)
20. Koski A, Raki M, Nokisalmi P, et al: Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther 20: 221-229, 2012.
21. Liu Y, Lu Z, Fan P, et al: Clinical efficacy of chemotherapy combined with verapamil in metastatic colorectal patients. Cell Biochem Biophys 61: 393-398, 2011.
22. Yi J, Yang J, He R, et al: Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 64: 108-116, 2004. (Pubitemid 38114088)
23. Jing Y, Yang J, Wang Y, et al: Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent. Free Radic Biol Med 40: 2183-2197, 2006. (Pubitemid 43903104)
24. Igarashi T, Izumi H, Uchiumi T, et al: Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26: 4749-4760, 2007. (Pubitemid 47093179)
25. Mwakigonja AR, Kaaya EE, Heiden T, et al: Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association. BMC Cancer 10: 344, 2010.
26. Mwakigonja AR, Pak F, Pyakurel P, et al: Oral Kaposi's sarcoma in Tanzania: presentation, immunopathology and human herpesvirus-8 association. Oncol Rep 17: 1291-1299, 2007.
27. Quan Z, Gu J, Dong P, et al: Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to cirsimaritin-induced apoptosis in human gallbladder carcinoma GBC-SD cells. Cancer Lett 295: 252-259, 2010.
28. Ding XW, Wu JH and Jiang CP: ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86: 631-637, 2010.
29. Abaan OD, Mutlu PK, Baran Y, Atalay C and Gunduz U: Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients. Cancer Invest 27: 201-205, 2009.
30. Donmez Y, Akhmetova L, Iseri OD, Kars MD and Gunduz U: Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother Pharmacol 67: 823-828, 2011.
31. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003. (Pubitemid 37487159)
32. Hait WN and Yang JM: The individualization of cancer therapy: the unexpected role of p53. Trans Am Clin Climatol Assoc 117: 85-101, 2006.
33. Tazzari PL, Cappellini A, Ricci F, et al: Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427-438, 2007.
34. Meurette O, Lefeuvre-Orfila L, Rebillard A, Lagadic-Gossmann D and Dimanche-Boitrel MT: Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations. Clin Cancer Res 11: 3075-3083, 2005. (Pubitemid 40525214)
35. Cole S P, Sparks KE, Fraser K, et al: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994. (Pubitemid 24375226)
36. Cullen KV, Davey RA and Davey MW: Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. Biochem Pharmacol 62: 417-424, 2001. (Pubitemid 32607723)
37. Barattin R, Perrotton T, Trompier D, et al: Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1. Bioorg Med Chem 18: 6265-6274, 2010.
38. Trompier D, Chang XB, Barattin R, du Moulinet D'Hardemare A, Di Pietro A and Baubichon-Cortay H: Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 64: 4950-4956, 2004. (Pubitemid 38924542)